UR Medicine's Wilmot Cancer Institute | Strategic Alliance Partners

home / sap-partner / cancer-centers / university-of-rochester-wilmot-cancer-institute

The University of Rochester’s Wilmot Cancer Institute provides world-class cancer care and conducts pivotal cancer research. The goal is to prevent and conquer cancer through innovation in science, patient care, education, and community outreach. Serving a 27-county area in upstate New York, Wilmot features an 87-bed flagship cancer center, 13 outpatient locations, one of New York state’s largest bone marrow transplant programs and more.

Connect with us:

Latest from UR Medicine's Wilmot Cancer Institute

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

By D. Ross Camidge, MD, PhD
Rahul Gosain, MD

November 20th 2024

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

By Anna Weiss, MD

November 14th 2024

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,

Dr. O'Regan on the RIGHT Choice Trial in HR+/HER2- Breast Cancer

By Ruth M. O'Regan, MD

March 21st 2023

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Carla Falkson, MBChB, MMed, MD, professor, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center,

Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer

By Carla Falkson, MBChB, MMed, MD

February 7th 2023

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer

By Ryan Scott

January 27th 2023

The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

By Ruth O'Regan, MD, University of Rochester Medical Center

August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

By Gina Mauro
Toni K. Choueiri, MD

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

By Gina Mauro
Tanya B. Dorff, MD

February 18th 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Personalized Medicine Shows Extended Reach Throughout Breast Cancer

By Caroline Seymour

November 18th 2021

Molecular markers, risk, and response are being used to better tailor escalated and de-escalated treatment approaches for women with breast cancer.

Dr. Falkson on the Potential to De-Escalate Chemotherapy in HER2+ Breast Cancer

By Carla Falkson, MBChB, MMed, MD

November 12th 2021

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Paul M. Barr, MD, of Wilmot Cancer Institute

Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLL

By Paul M. Barr, MD
Paul Barr, MD

July 15th 2021

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, of the Wilmot Cancer Institute

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

By Paul M. Barr, MD

June 30th 2021

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

By Paul M. Barr, MD

June 11th 2021

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

By Jessica Hergert

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.